Prespecified secondary analysis of the STEP-HFpEF trials (1,145 participants with obesity-related HFpEF): semaglutide 2.4 mg weekly vs placebo improved KCCQ-CSS and body weight consistently across age groups from <55 to ≥75 (p-interaction 0.80 and 0.41).
Secondary analysisn = 1,145
Pandey et al. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme